Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LA-rFVIIa prophylaxis dose-finding trial in hemophilia with inhibitors
2008-006424-54Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eptacog alfa pegol (activated) in hemophilia A and hemophilia B (HB) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Frequency of adverse events, serious adverse events, and medical events of special interest and Potential immunogenicity of eptacog alfa pegol. Started Mar 2009; status: completed.
02
Drugs
eptacog alfa pegol (activated)
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2008-006424-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006424-54.